Switching to secukinumab in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country.
Aastha GuptaKabir SardanaRam K GautamPublished in: Tropical doctor (2019)
Several biological agents have been approved for the treatment of recalcitrant psoriasis. However, there is a lack of a consensus algorithm guiding the drug selection for patients who have failed conventional drugs. In cases not improving with cyclosporine, direct switching to a biological therapy usually leads to a disease flare owing to increased production of interleukin (IL)-17A. Thus, secukinumab, a rapidly acting anti-IL-17A drug, may be ideal in such situations.
Keyphrases
- ankylosing spondylitis
- end stage renal disease
- ejection fraction
- newly diagnosed
- machine learning
- adverse drug
- prognostic factors
- high dose
- peritoneal dialysis
- deep learning
- rheumatoid arthritis
- systemic lupus erythematosus
- patient reported outcomes
- cell therapy
- clinical practice
- hepatitis c virus
- atopic dermatitis
- patient reported
- mesenchymal stem cells
- replacement therapy
- antiretroviral therapy